Patients with COVID-19 who are admitted with respiratory distress will be considered for enrollment on this study. Patients will be screened and then if they meet eligibility criteria will be enrolled. Abatacept will be administered on Day 1 at a dose of 10 mg/kg. Patients will then be followed closely through 90 days post-treatment.
Developed by the Division of Clinical Informatics at Beth Israel Deaconess Medical Center, Alicanto™ is an online collaboration platform for learning, group collaborations, and clinical care coordination used at Harvard hospitals. Learn more at Alicanto Cloud.
Alicanto is developed by The Division of Clinical Informatics one of the first academic divisions in the world to concentrate on the use of computers for patient care, teaching, and medical research.
DCI is part of Beth Isreal Deaconess Medical Cented a world-class teaching hospital of Harvard Medical School located in the heart of Boston.
Powered by Alicanto Cloud and Opigno